Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

 https://pubmed.ncbi.nlm.nih.gov/35749758/

Lemborexant (LEM) is a dual orexin receptor antagonist approved for the treatment of insomnia in adults in multiple countries including the United States, Japan, Canada, Australia and several Asian countries.

Conclusions: For all doses, LEM demonstrated abuse potential versus PBO and appeared to have a similar abuse potential profile to Zolpidem (ZOL) and Suvorexant (SUV) in this study population. Lemborexant was well tolerated. Lemborexant has been placed in Schedule IV, the same drug schedule as ZOL and SUV.

Popular posts from this blog

Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, and Addiction Care Settings

Prescription Drug Misuse and Addiction: Compassionate Care for a Complex Problem

International Overdose Awareness Day, August 31